A recent animal study showed that buparlisib could significantly inhibit tumor growth and promote infiltration of human CD45+ cells and CD3+ T cells in humanized mice xenografted with PIK3CA-mutated human bladder cancer cells [143]. Here, PIK3CA is linked to urinary bladder cancer.